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SUMMARY
A diminished gamma-interferon (IFN-gamma) production by T cells from patients with rheumatoid
arthritis (RA) in response to autologous stimulation coincides with a defective regulation of Epstein-Barr
virus (EBV) transformation and is in part due to monocyte-produced interleukin-1 (IL-1) inhibitor and
prostaglandins. Since IL-2 can act directly on unstimulated T-cells to induce IFN-gamma production we
have now examined the effect of recombinant IL-2 (rIL-2) on purified resting T lymphocytes from RA
patients. Treatment with rIL-2 (25 U/ml) of lymphocytes from 15 controls led to an increased production of
72-h supernatant EBV-inhibitory activity (19±4% SE without; 48±7% with rIL-2), but had only minimal
or no effect on gamma-interferon production by E-rosetting lymphocytes from 15 patients with active RA.
This defect could not be corrected by adding indomethacin to RA cultures.
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RHEUMATOID arthritis (RA) is associated with
subtle immunoregulatory defects that can be in
part recognized in the deficient autologous
mixed leucocyte reaction (AMLR) [1-3] and in
the in vitro and in vivo abnormalities relating to
Epstein-Barr virus (EBV) infection [3-10]. We
have previously presented evidence that a
diminished gamma-interferon (IFN-gamma)
production by RA T lymphocytes coincides with
a defect of the suppression of the EBV-induced
DNA-synthesis [3]. The suppression of EBV-
induced B cell proliferation by AMLR-superna-
tants can be blocked with monoclonal antibody
against IFN-gamma which indicates that this
assay can be used for detecting small amounts of
IFN-gamma [3]. The impaired IFN-gamma pro-
duction is observed when the RA T cells interact
with autologous non-T lymphocytes and may be
due in part to prostaglandin and IL-1 inhibitor
produced by the adherent cell population [8, 9].
In contrast, when activated by monocyte-
depleted AMLR stimulator cells, the RA T lym-
phocytes can then produce IFN-gamma in
normal amounts [8,9]. AMLR proliferative
response and IFN-gamma generation are signifi-
cantly associated with the production of IL-2 [1,
9, 11-13], which may itself be modulated by
monocyte-mediated events [9, 14, 15]. IL-2 can
also act directly on unstimulated T cells to
induce IFN-gamma production without induc-
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tion of a mitogenic response [12]. In different
assay systems, RA lymphocytes produced less
IL-2 than normals and responded poorly to
exogenous IL-2 [1,16,17]. This study was under-
taken to examine the effect of rIL-2 on RA T
lymphocytes in the absence of mitogens or
AMLR stimulator cells.
MATERIALS AND METHODS
Subjects
Heparinized venous blood was obtained from
15 patients with definite or classical active RA,
aged 39-75 (mean 58) years [18]. The control
population consisted of 12 normal blood-donors
aged 27-76 (mean 45) years. Three patients with
active seronegative spondarthropathies all
taking nonsteroidal anti-inflammatory drugs
(NSAIDs) (two with psoriasis and polyarticular
arthritis, one with ankylosing spondylitis, aged
44, 76 arid 18 years) were added to the healthy
control group. All of the RA patients were
taking NSAIDs and, in addition, 11 of the RA
patients were receiving either chloroquine, gold
or D-penicillamine. Two RA patients were also
being treated with small doses (<10 mg/d) of
prednisone.
Cell separation
Peripheral-blood mononuclear cells (PBM)
were obtained from heparinized venous blood
by Ficoll-Hypaque density-gradient centrifuga-
tion, and E-rosetting lymphocytes were sep-
arated from non-T cells by erythrocyte-rosetting
with 2-aminoethylisothiouronium hydro-
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bromide (AET, Sigma, St. Louis, MO) treated
sheep red blood cells [19]. PBM were depleted
of adherent cells by passage through G-10
Sephadex columns [20] in RPMI 1640 sup-
plemented with 10% heat-inactivated FCS. The
resultant E+ cell population contained >90%
E-rosetting cells and less than 2% esterase posi-
tive cells.
Peripheral blood mononudear cell proliferative
responses
Adherent cell-depleted lymphocytes were
cultured in 0.2 ml RPMI 1640-10% FCS sup-
plemented with 2 n\M glutamine and gen-
tamycin (10 |xg/ml) in 96-well flat-bottomed
Linbro plates (Flow Laboratories, Hamden,
CT) in the presence or absence of recombinant
IL-2 (gift from Biogen S.A., Geneva). Cells
were pulsed with (3H) thymidine (1 uCi/well;
sp.act. 5 Ci/mmol, Amersham Corp.) for the last
18 h of incubation. The cultures were harvested
on day 3 with a semi-automated multiple-sample
harvester (MASH) device. Data are expressed
in cpm ± SEM (n = 4).
Preparation of supernatants
T cell derived supernatants were produced in
the presence and absence of rIL-2 (25 U/ml) in
2 ml RPMI-10% FCS at a cell density of 106
cells/ml. After 72 h, the supernatants were
recovered and filtered through 0.45 urn mem-
branes (Millipore Corp., Bedford, MA). The
supernatants were stored at —70°C until used.
EBV and interferon assay
Transforming virus was obtained from the
supernatants of the EBV-secreting B 95-8 mar-
moset lymphoblastoid cell line. Double-rosetted
normal non-T cells were infected with EBV, and
the effect of 72-h culture supernatants on EBV-
induced DNA synthesis was assessed by measur-
ing (3H) thymidine incorporation on day 10 as
described [3]. The data obtained are expressed
as percentage suppression calculated as:
Percentage suppression =
(cpm in supernatant-treated cultures) \
(cpm in control cultures) J x 100.
Gamma-interferon was measured using a radio-
immunoassay (Centocor, Malvern, PA) [21].
Prostaglandin and IL-2 assay
Culture fluids were assayed for PGE2 and for
IL-2 as previously described [22].
Monoclonal anti-Tac antibody and control
ascites was provided by T. A. Waldmann, NIH
[23].
Student's t test was used to determine the
significance of differences between groups.
RESULTS
In the presence of rIL-2, unstimulated
E-rosetting lymphocytes from 15 controls
released factor(s) into the culture medium which
suppressed EBV-induced DNA synthesis as an
index of IFN-gamma production (Fig. 1). EBV-
induced B cell proliferation, measured 10 days
after virus infection, was inhibited by 72-h cul-
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FIG. 1.—The effect of rIL-2 on the production of a super-
natant inhibitory factor by E-rosctting lymphocytes.
2x l l fT cells from 12 normal controls (O), three patients
with scroncgative spondarthropathies ( • ) and 15 RA
patients were incubated in 0.2 ml RPMI 1640-10% FCS in
the presence and absence of rIL-2 (25 U/ml). Superna-
tants collected at 72 h were tested for their ability to sup-
press EBV-induced DNA synthesis. The results arc
expressed as the mean percentage suppression of (3H)
thymidine incorporation compared with control cultures
at 10 days post EBV infection (mean control counts from
six experiments = 67811 cpm). Error bars represent the
mean ± SEM for all individuals in the designated groups.
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ture supernatants from 19.2%±4.0 (mean ±
SE) without rIL-2 to 47.8%±6.5 at an rIL-2
concentration of 25 U/ml (p < 0.001). R IL-2
had no direct inhibitory effect on EBV-induced
B lymphoblast transformation. Tested on three
occasions at 4-week intervals, the IL-2-induced
IFN-gamma response from the same normal
donor (E.F.) was similar. Three patients with
active seronegative spondarthropathies treated
with NSAIDs responded similarly to normal
donors. In contrast to the inhibitory activity on
EBV-induced DNA synthesis generated by T
lymphocytes from controls in response to rIL-2,
the E-rosetting lymphocytes from 15 RA
patients did not generate this inhibitory activity
in response to rIL-2.
To confirm that the EB V inhibitory factor was
specifically induced by rIL-2, a monoclonal anti-
body against IL-2 receptor was added at a final
concentration of 1:2000 to the culture of a
normal donor. At the two concentrations of
rIL-2 tested, Tac antibody abrogated completely
the induction of interferon (Fig. 2). Tac antibody
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FIG. 2.—The effect of Tac monoclonal antibody on the
production of a supernatant inhibitory factor by E-roset-
ting lymphocytes from a normal control stimulated with
rIL-2. E-rosetting cells were exposed to rIL-2 in absence
( ) or presence of control ascites at 1:2000 ( ) for
72 h. Tac antibody was added to the cell cultures prior to
the addition of rIL-2 at a final concentration of 1:2000
( ). Supernatants collected at 72 h were tested for
their ability to suppress EBV-induced DNA synthesis.
Results are indicated as the SEM of quadruplicate culture.
Numbers in brackets represent U/ml of IFN-gamma
measured by radio-immunoassay as described in Materials
and Methods.
and control ascites had no significant direct
effect on EBV-induced proliferation.
Since a small quantity of adherent cells
(judged by esterase staining) always con-
taminated our cultures (<2%) and since prosta-
glandins produced by these adherent cells can
decrease IFN-gamma generation, indomethacin
(1 ng/ml) was added to the cell cultures. PGE2
concentration in non-indomethacin-treated cul-
tures was <4 ng/ml and indomethacin did not
affect interferon activity of supernatants (three
of three experiments with RA cells, data not
shown).
A difference in subsets of lymphocytes or
spontaneous IL-2 release due to separation tech-
niques or disease might contribute to1 the RA
defect. To test this possibility, lymphocytes were
examined for surface phenotypes and the corre-
sponding cell-culture supernatants, stimulated
or unstimulated with rIL-2, were examined for
EBV-suppressive activity. In two of two experi-
ments, both rIL-2 responding controls and non-
responding RA patients showed similar ratios of
OKT3, OKT4 and OKT8 subpopulations (data
not shown). IL-2 concentration in unstimulated
72-h T cell supernatants from three control and
three RA cultures was <0.01 U/ml.
A difference in supernatant EBV inhibitory
activity might be paralleled by a difference in the
proliferation of the control and RA lymphocytes
exposed to rIL-2. As shown in Table I, (3H)
thymidine incorporation on day 3 by purified T
lymphocytes was no different in normal and RA
cells in the presence or absence of rIL-2.
Using a radio-immunoassay (Centocor IFN-
gamma RIA), when the supernatant EBV
inhibitory activity was high, gamma-interferon
level paralleled the percentage suppression of
EBV-induced DNA synthesis (Table II). rlL-
2-induced IFN-gamma production by normal
cells could be inhibited by the addition of Tac
antibody (Fig. 2) and no IFN-gamma was found
in non-EBV-inhibitory RA T cell supernatants
(Table II).
DISCUSSION
We have confirmed that peripheral-blood T
lymphocytes from RA patients are deficient in
their response to IL-2 [1,16,17]. We have shown
that unstimulated T cells from normal controls
and patients with spondarthropathies in the
presence of rIL-2 produce sufficient amounts of
gamma-interferon to inhibit in vitro EBV-
induced B cell proliferation. By contrast, RA
E-rosetting lymphocytes are deficient in their
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Donor
1
2
3
4
5
Medium
1278±177
382 ± 35
1064 ±328
824±211
687± 80
PROLIFERATIVE
Controls
rIL-2t
1384±276
429+112
1198±409
585+173
783± 49
TABLE I
RESPONSE OF E-ROSETTING LYMPHOCYTES
PHAt
82458±2082
76890±2581
106614+3269
64803±2948
20272± 402
Medium
658±104
53O± 16
1522±975
1443±561
411± 53
*
RA patients
rIL-2t
673± 33
321 ±106
613+112
1491 ±598
381± 59
PHAt
60527 ±2940
87530±1502
66701 ±3945
35OO3±1951
15509 ±1089
Results are expressed in cpm ± SEM (n = 3).
* [3H] thymidine incorporation was assessed on day 3 after an 18 h pulse.
t rIL-2 concentration was 25 U/ml.
$ PHA concentration was 1 ug/ml.
ability to respond to exogenous IL-2. Our data
clearly demonstrated that purified rIL-2 is not
mitogenic [12], and the difference in IFN-
gamma production observed between normal
and RA lymphocytes can therefore not be
explained by a difference in proliferation.
Recently, we have shown that diminution of
IFN-gamma generation by RA cells was not due
to the effects of either chronic inflammatory
disease or drug therapy [3]. The IL-2 and IFN-
gamma defect(s) are complex and may involve
multiple cell interactions. Preactivated RA-T
cells absorb smaller amounts of IL-2 than con-
trol cells suggesting that they have fewer or less-
functional IL-2 receptors on their surfaces [16,
17]. Exogenous IL-2 failed to normalize the
defective AMLR proliferative response in RA
patients [1]. IL-2 regulates the subsequent pro-
duction of IFN-gamma from T-cells [12] and
monocytes are not required for its induction
[24]. Kasahara et al. [12] have shown that IL-2
acts directly on unstimulated T cells to induce
IFN-gamma production without induction of a
mitogenic response. Both natural killer cells and
T cells have been shown to produce IFN-gamma
in response to IL-2 [12, 13]. Since our assay
system was not designed to detect natural killer
cells, we cannot exclude the possibility that IFN-
gamma was produced by rIL-2 stimulation of
these cells. In RA, the production of both lym-
phokines is down-regulated by monocyte-medi-
ated events [3,8,9]. We have previously shown
that the diminished EBV-suppressor-factor gen-
eration by autologously-activated RA T cells or
a T cell subset is related in part to their increased
sensitivity to PGE [8]. Lotz et al. have demon-
strated that EBV-related T cell defects in RA
could be explained on the basis of a monocyte
produced IL-1 inhibitor [9]. RA T cells were not
detectably defective in their IFN-gamma pro-
duction when stimulated by allogeneic non-T
cells [3] or autologous monocyte-depleted EB V-
infected B-cells [9]. Indomethacin treatment of
our adherent cell-depleted RA E-rosetting lym-
phocytes did not correct their diminished
responsiveness to exogenous IL-2. Thus, the
rIL-2 deficiency of RA-blood T lymphocytes
appears to be a distinct cellular defect not
directly related to in vitro PGE or IL-1 inhibitor
effects. We cannot exclude the possibility that
the exposure of lymphocytes to prostaglandins
or IL-1 inhibitor in vivo or the presence of
inhibitory cells such as in SLE may have affected
the RA cell response [25].
Our study has confirmed the deficiency of RA
peripheral blood lymphocytes to exogenous IL-2
and has demonstrated an impaired IFN-gamma
TABLE II
CORRELATION OF PERCENTAGE SUPERNATANT-MEDIATED
INHIBITION OF EBV-INDUCED B CELL PROLIFERATION
WITH IFN-GAMMA LEVEL AS ASSESSED BY RADIO-
IMMUNOASSAY
Donor* rIL-2t Percentage
suppression*
IFN-gamma§
(U/ml)
RA 1
RA2
Control 1
Control 2
Control 3
10
10
25
16
0
42
6
53
8
91
0
0
2
2
0
5.6
0
10.5
0.25
80.5
* T cell supernatants were obtained after 72 h of culture.
12x10* E-rosetting lymphocytes were cultured with (+)
or without ( - ) 25 U/ml rII-2.
t Results are expressed as the mean of two determinations
of percentage suppression of EBV-induccd B cell pro-
liferation compared with control cultures at 10 days post
EBV infection as described in Materials and Methods.
§ Data arc expressed as the mean of two determinations of
IFN-gamma as described in Materials and Methods.
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production by unstimulated RA T cells in
response to rIL-2.
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NOTICES
THIRTY-THIRD ANNUAL MEETING OF THE VIGGO PETERSEN CENTRE:
RHEUMATOLOGY UPDATE 1988
President: Prof. S. de Seze
Organizing Committee: Profs. A. Ryckewaert, M. F. Kahn, D. Kuntz, A. Dryll and Dr. Cl. Guerin.
Dates: 17-18 March 1988.
Venue: Palais des Congres, Paris.
Further information: Melle C. Moroy, Centre Viggo Petersen, 6 Rue Guy Patin, 75010, Paris.
ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES: 250TH ANNIVERSARY
INTERNATIONAL CONFERENCE ON RHEUMATOLOGY
Dates: 14-16 April 1988.
In 1988 the Royal National Hospital for Rheumatic Diseases will be celebrating its 250th annivers-
ary. The major event of the seven-month programme will be an international conference focusing on
both historical aspects and state of the art lectures from world-renowned authorities.
For further information contact: Andrei Calin, MD FRCP, Royal National Hospital for Rheumatic
Diseases, Upper Borough Walls, Bath BA1 1RL, UK.
Tel.: (0225) 65941.
INTERNATIONAL SOCIETY FOR PROSTHETICS AND ORTHOTICS
SCIENTIFIC MEETING
Dates: 18-20 April 1988.
Venue: University of Bath.
Further details: Dr. B. McHugh, ISPO Bath 88, National Centre for Training and Education in
Prosthetics and Orthotics, University of Strathclyde, Curran Building, 131 St. James Road, Glasgow
G4 0LS.UK.
FOURTH MEDITERRANEAN CONGRESS OF RHEUMATOLOGY
FIRST MEDITERRANEAN SYMPOSIUM ON BEHCET'S DISEASE
Dates: 2-3 June and 4 June 1988.
Venue: Atatiirk Cultural Centre, Istanbul, Turkey.
Main topics: Juvenile chronic arthritis, familial Mediterranean fever, amyloidosis associated with
rheumatic diseases, vasculitis in Behcet's disease.
Further information: Prof. N. Dilsen, Istanbul Faculty of Medicine, Division of Rheumatology,
Capa, Topkapi, Istanbul, Turkey.
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